Rezolute is trading at $4.61, up 5.25% in live trading on October 8, 2026; no clear company-specific catalyst has been identified.
- Rezolute’s investor-relations page lists its latest release on October 5, concerning an FDA-recommended pre-BLA meeting. That update is prior context, not a confirmed cause of today’s rise.
- The biotech sector is down, so sector weakness does not explain Rezolute’s move higher.